Bruker Corporation · NASDAQ:BRKR
Bruker — 28th J.P. Morgan Healthcare Conference (January 2010)
24 slides from Bruker's conference presentation, Jan 13, 2010
Slide 1: Bruker Corporation 28th J.P. Morgan Healthcare Conference
Bruker Corporation (BRKR) 28th J.P. Morgan Healthcare Conference January 13, 2010 Frank Laukien, President and CEO Brian Monahan, Chief Accounting Officer (appointed CFO as of Feb. 1, 2010)
Slide 2: Safe Harbor Statement
Bruker Corporation Safe Harbor Statement Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are
Slide 3: Bruker Overview
Premier Brand with Leading Market Share in Key Markets High-Performance Life-Science Tools Focused Company with Diverse Customer Base Experienced Management Team Efficient CapEx And Deleveraging, Positioned for Earnings Growth Proven Innovator with Extensive Proprietary Technology Portfolio Compelli
Slide 4: Global Company with Diversified Markets
Global Company with Diversified Markets Excellent Reputation in High-Performance Life Science Tools and Analytical Solutions Other Significant R&D, Production Sites Direct Sales Offices Major DE, CH & FR R&D and Production Sites Additional distributors around the world Headquarters Key Markets: Life
Slide 5: Investment Highlights
Bruker Corporation Investment Highlights Very Strong 2009 New Product Flow Leading technology provider with 12% R&D investment in 2008 Positioned for revenue growth and margin expansion in 2010-2012 Anticipated Significant Benefits from Global Stimulus ~68% of revenue from academia, non-profits, and
Slide 6: Analysis of 2008 Bruker Revenue Customer Mix
Analysis of 2008 Bruker Revenue Customer Mix Positioned Bruker to Weather Recession and Benefit from Stimulus Programs Revenue by Customers Revenue by Geography* 2008 Annual Revenue: $1.1 Billion Stimulus funding and supplementary budgets can cushion recession, and may provide significant upside Rev
Slide 7: Financial Strategy and Margin Opportunities of Bruker Scientific Instruments Segment
Financial Strategy and Margin Opportunities of Bruker Scientific Instruments Segment Bruker BioSpin and Bruker Optics: established, market-leading, profitable divisions Goals: incremental margin improvements, operational excellence and improvements in balance sheet metrics and cash flow Newer divisi
Slide 8: Key Financials: Growth, Margins & Cash Flow
Key Financials Growth, Margins & Cash Flow Q3-09 YTD vs. Q3-08 YTD Financial Results: GAAP Revenue: $748.1M vs. $791.9M, GAAP: 5.5% decline; FX-adjusted: 0.5% increase Operating Income: $60.5M vs. $59.3M Net Income: $37.7M vs. $38.7M GAAP EPS: $0.23 vs. $0.23 Cash Flow from Operations: $67.3M vs. $1
Slide 9: Selected Balance Sheet Metrics: Operational Excellence & Lean Initiatives
Selected Balance Sheet Metrics Operational Excellence & Lean Initiatives $0.08 reduction from 2006 to Q3 2009 equates to $88M of lower working capital to support revenue run-rate expect further reduction in working capital/revenue ratio with goal of additional $100M of cash from balance sheet over s
Slide 10: Systems Orders Received in H2-2009 from Global Stimulus Programs
Over 100 Systems Orders Received in H2-2009 from Global Stimulus Programs Most stimulus orders are for high-end instrumentation (NMR, preclinical MRI, mass spectrometry and X-ray) Average selling prices ~$500,000 per system; cumulative amount already received in H2-2009 >$70 million Stimulus orders
Slide 11: AXS: Unique, High-Performance Systems for Broader Markets
Bruker AXS Unique, High-Performance Systems for Broader Markets and New Users 2008 PITTCON Editor’s Gold and R&D 100 Award Winner SMART X2S World’s First Fully Automated Molecular Structure Machine New: Pittcon 2009 S8 LION Simultaneous WD-XRF Spectrometer for Quality and Process Control New: Pittco
Slide 12: Optics: Infrared and Raman Spectroscopy
Bruker Optics Infrared and Raman Spectroscopy for Research and Applied Markets FT-IR, FT-NIR and Raman platforms Strong presence in laboratory analysis, industrial R&D, academia, government A leader in pharma PAT (Process Analytical Technology) and ‘pharma forensics’ Diverse industrial and research
Slide 13: Bruker BioSpin: Quantum Jumps in Performance in NMR
13 Bruker BioSpin Quantum Jumps in Performance for Global Technology and Market Leadership in NMR Nov. 2008: Saudi KAUST order of 10 NMR systems for ~$20M (partially delivered) 3 New Unique Ultra-High Field NMR Magnet Introductions in 2009 World’s highest field, actively shielded widebore magnet 900
Slide 14: BioSpin: World's First Solid State DNP-NMR Spectrometer
Bruker BioSpin World’s First Solid State DNP-NMR Spectrometer with >50x Signal Enhancement for Bio-Solids World’s first Commercial solid state Dynamic Nuclear Polarization (DNP)-NMR spectrometer, co-developed with MIT Polarization enhancement yields factor 50-150x gain in sensitivity for Solid State
Slide 15: Bruker BioSpin: New Initiatives in Pre-clinical Molecular Imaging
15 Bruker BioSpin New Initiatives in Pre-clinical Molecular Imaging September 2009 – New Collaboration with Aspect Magnet Technologies for 1 Tesla desktop system for preclinical MRI September 2009 - Memorandum of understanding (MOU) with Philips Healthcare for development of preclinical Magnetic Par
Slide 16: BioSpin EPR e-scan Analyzers for SABMiller Breweries
Bruker BioSpin EPR based e-scan Analyzers to enable Beer Quality Control at SABMiller’s Latin American Breweries Framework Agreement for a $1M order announced on January 5, 2010 Bruker's proprietary EPR (Electron Paramagnetic Resonance) technology enables rapid quality control in beer production pro
Slide 17: Bruker Daltonics: Across-the-board New Technology Platforms
maXis UHR-TOF: ultra-high MS performance at UHPLC speed (ASMS 2008) amaZon ion trap: fastest trap in the world at UHPLC speed, unique high-sensitivity ETD (ASMS 2009) ultrafleXtreme MALDI TOF/TOF : first total 1000Hz TOF/TOF, superior MALDI imaging tool, Edmass top-down protein sequencing (ASMS 2009
Slide 18: Daltonics New Opportunities: MALDI Biotyper
Bruker Daltonics New Opportunities MALDI Biotyper for Microorganism Molecular ID Higher Specificity, Faster Time-to-Result, Lower Cost Highly specific species ID of bacteria, fungi, yeasts ID in mixtures Minimal sample prep, fast results Proprietary, high quality protein fingerprint database Lower c
Slide 19: Bruker Detection: CBRNE Detection for Defense and Homeland Security
Bruker Detection Corporation Chemical, Biological, Radiological, Nuclear and Explosives Detection for Defense and Homeland Security January 2010: Announced Phase IIIb Advancement within DHS ‘Autonomous Rapid Facility Chemical Agent Monitor’ Program Next-Gen IMS explosives detection - launch planned
Slide 20: Energy & Supercon Technologies: Emerging Business with Separate Strategy
Bruker Energy & Supercon Technologies Emerging Business in Different Sector with Separate Strategy Division in Alternative Energy Sector with Emerging Large Addressable Markets: Q3-09 YTD Revenue $36.0M, Net Loss ($5.0M) expect rapid growth in Q4-2009 Goals: aggressive investment in new products and
Slide 21: Bruker Energy & Supercon Technologies: Expected Multi-billion $ Market Potential
21 Bruker Energy & Supercon Technologies Expected Multi-billion $ Market Potential
Slide 22: Bruker Energy & Supercon Technologies: Investment in New Opportunities
22 Advanced low-temperature superconductors (LTS) for clinical MRI, NMR, EPR and FTMS magnets, and fusion energy projects (e.g. ITER) Medium-temperature superconductors (MTS) MgB2 wires for future cryofree MRI magnets 1G BSSCO and 2G YBCO high-temperature superconductors (HTS) and HTS cables Next-ge
Slide 23: $36 Million Contract from ITER Fusion Energy Project
Bruker Energy & Supercon Technologies (BEST) $36 Million Contract from ITER Fusion Energy Project $36 million contract to supply 37 metric tons of high-performance niobium-tin superconductor Expected shipping in H2-2010, with deliveries over 30 months thereafter ITER is a multi-billion $ internation
Slide 24: www.bruker.com
www.bruker.com
Bruker — 28th J.P. Morgan Healthcare Conference (January 2010) on 6ix